More Genetic Tests May Benefit Ashkenazi Jewish Cancer Patients

Share this content:
More Genetic Tests May Benefit Ashkenazi Jewish Cancer Patients
More Genetic Tests May Benefit Ashkenazi Jewish Cancer Patients

TUESDAY, July 25, 2017 (HealthDay News) -- For Ashkenazi Jewish patients with breast cancer, comprehensive sequencing identifies pathogenic mutations in genes other than BRCA1 and BRCA2 founder alleles, according to a study published online July 20 in JAMA Oncology.

Tom Walsh, Ph.D., from the University of Washington in Seattle, and colleagues sequenced genomic DNA of 1,007 women who identified themselves and all four grandparents as Ashkenazi Jews, participating in the New York Breast Cancer Study (NYBCS).

The researchers found that 903 probands had no founder mutations in BRCA1 or BRCA2; of these, 0.8 percent carried another pathogenic mutation in BRCA1 or BRCA2, and 3.4 percent carried a pathogenic mutation in another breast cancer gene (29 in CHEK2, and one each in BRIP1 and NBN). Of the inherited predispositions to breast cancer in the NYBCS, 73.8, 4.9, and 21.8 percent were due to a BRCA1 or BRCA2 founder allele, another BRCA1 or BRCA2 mutation, and a mutation in another gene, respectively. Of the Ashkenazi patients with breast cancer in the NYBCS, 14.1 percent had a germline mutation responsible for their disease: 11.0 and 3.1 percent in BRCA1 or BRCA2 and in CHEK2 or another breast cancer gene, respectively. Overall, 51.4 percent of the 111 patients with BRCA1 or BRCA2 mutations had a mother or sister with breast or ovarian cancer; 48.6 percent did not.

"Comprehensive sequencing would provide complete relevant genetic information for Ashkenazi Jewish patients with breast cancer," the authors write.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Even Overdose Doesn't Stop Opioid Prescribing

Even Overdose Doesn't Stop Opioid Prescribing

Few receive medication-assisted treatment after hospital discharge, researchers find

NT-ProBNP-Guided Treatment No Benefit in High-Risk HFrEF

NT-ProBNP-Guided Treatment No Benefit in High-Risk HFrEF

No improvement in clinical outcomes versus usual care in heart failure and reduced ejection fraction

Oral Corticosteroids No Benefit for LRI in Non-Asthmatic Adults

Oral Corticosteroids No Benefit for LRI in Non-Asthmatic ...

No decrease in cough duration, severity for adults without asthma with lower respiratory tract symptom

is free, fast, and customized just for you!

Already a member?

Sign In Now »